websites. All patients offered written informed consent just before enrolment to the study. An interactive voice response program was utilised to randomly assign patients in a one:one ratio to fl udarabine plus alemtuzumab or fl udarabine monotherapy in an open label trial.
Showing posts with label SNDX-275. Show all posts
Showing posts with label SNDX-275. Show all posts
Thursday, August 23, 2012
Third Party Documentation Exposes An Unanswered Questions About mTOR Inhibitors
This study was accredited by the institutional evaluation board or ethics committee from every single of the participating websites. All patients offered written informed consent just before enrolment to the study. An interactive voice response program was utilised to randomly assign patients in a one:one ratio to fl udarabine plus alemtuzumab or fl udarabine monotherapy in an open label trial.
websites. All patients offered written informed consent just before enrolment to the study. An interactive voice response program was utilised to randomly assign patients in a one:one ratio to fl udarabine plus alemtuzumab or fl udarabine monotherapy in an open label trial.
Subscribe to:
Posts (Atom)